Clinical Trials

Clinical Trial Detail

Return to search results.

A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations

Complete title: A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects with Advanced Non-Small Cell Lung Cancer and BRAF Mutations

Research Study Number       20111838
    
Principal Investigator       Christina Baik
    
Phase       II

Look up trial at NIH

Research Study Description

GSK2118436 is a potent and selective inhibitor of BRAF kinase activity. BRF113928 is a Phase II, non-randomized, open-label study to assess the efficacy, safety, and tolerability of GSK2118436 administered as a single agent to subjects with BRAF mutant advanced non-small cell lung cancer. Subjects will receive GSK2118436 150 mg twice daily (BID) and continue on treatment until disease progression, death, or unacceptable adverse event.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

Exclusion Criteria:

Other exclusion criteria may apply.



Research Study Number       20111838
    
Contact       Seattle Cancer Care Alliance Intake Office
    
Telephone       800-804-8824 / 206-288-1024
    
   

Keywords
Lung Cancer; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.